PIR International interview with Paul Sekhri, President & CEO, vTv Therapeutics
PIR International recently interviewed Paul Sekhri, a seasoned leader with over 35 years of experience in the life sciences industry. His career spans senior leadership roles in major pharmaceutical and biotech companies, as well as private equity and venture capital. He is currently the President and CEO of vTv Therapeutics, Inc., and has previously led eGenesis, Inc. Sekhri has served on over 35 boards, including Veeva Systems, Compugen Ltd., and The Metropolitan Opera, and was recently nominated as Chairman of the Board of Trustees of Young Concert Artists, Inc.
Reflecting on his career milestones, Sekhri highlighted his leadership of four biotech companies, senior positions at Novartis, Teva, and Sanofi, and extensive board experience, including 18 chair roles. He credits his first industry manager, Peter Savas, and his mentor at Millipore, Tim Leahy, as key influences in his career.
When asked about the attributes of an outstanding leader, Sekhri emphasized the ability to synthesize disparate information, truly listen rather than simply waiting to respond, and recognize patterns to navigate familiar challenges. Leading high-performing, multi-generational teams in a hybrid work culture requires a flexible communication approach, including regular in-person meetings—something he prioritizes with his leadership team in New York.
On fostering cultural diversity, Sekhri noted that being an LGBTQ+ leader has shaped his approach, alongside a commitment to expanding his reach to build truly diverse teams.
Discussing the "Biotech Winter" since 2022, he stressed the importance of always raising funds, accepting financing when offered, diversifying the investor base, and staying focused on value inflection points rather than dilution concerns. He remains optimistic about a thaw but recognizes the cyclical nature of the industry.
Regarding the Inflation Reduction Act (IRA) of 2022, Sekhri takes a pragmatic stance, choosing not to dwell on factors beyond his control. On AI’s impact, he foresees limited operational changes for his own business but expects significant transformation in early research and later-stage development across the industry.
Outside of work, Sekhri finds balance through classical music, a lifelong passion. Originally training as a pianist, he now channels his love for music into his leadership role at Young Concert Artists, supporting the next generation of world-class musicians.
He shared his excitement about vTv Therapeutics' work, particularly a potential breakthrough for Type 1 diabetes patients—developing the first therapeutic agent since insulin to reduce hypoglycemic events.
Offering advice to his younger self, Sekhri encouraged trust in the unfolding of life. His words of wisdom? “You have two ears and one mouth for a reason.” And above all, “Only connect—people do business with people, not companies.” Finally, he reflected on an important life lesson: karma is real.
